Catalyst Pharmaceuticals, Inc. (CPRX)
NASDAQ: CPRX · Real-Time Price · USD
21.12
-0.03 (-0.14%)
Nov 21, 2024, 4:00 PM EST - Market closed
Catalyst Pharmaceuticals Stock Forecast
Stock Price Forecast
The 7 analysts with 12-month price forecasts for CPRX stock have an average target of 31.14, with a low estimate of 23 and a high estimate of 36. The average target predicts an increase of 47.44% from the current stock price of 21.12.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for CPRX stock from 7 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jun '24 | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Buy | 2 | 2 | 2 | 2 | 2 | 3 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 6 | 6 | 6 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Stephens & Co. | Stephens & Co. | Buy Initiates $35 | Buy | Initiates | $35 | +65.72% | Nov 18, 2024 |
| Truist Securities | Truist Securities | Strong Buy Maintains $30 → $36 | Strong Buy | Maintains | $30 → $36 | +70.45% | Nov 11, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $30 | Strong Buy | Reiterates | $30 | +42.05% | Nov 8, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $26 → $30 | Strong Buy | Maintains | $26 → $30 | +42.05% | Aug 12, 2024 |
| Citigroup | Citigroup | Strong Buy Maintains $27 → $31 | Strong Buy | Maintains | $27 → $31 | +46.78% | Aug 9, 2024 |
Financial Forecast
Revenue This Year
485.78M
from 398.20M
Increased by 21.99%
Revenue Next Year
572.98M
from 485.78M
Increased by 17.95%
EPS This Year
1.18
from 0.63
Increased by 87.81%
EPS Next Year
1.53
from 1.18
Increased by 29.31%
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 508.9M | 614.7M | 746.6M | ||
| Avg | 485.8M | 573.0M | 660.4M | ||
| Low | 462.1M | 526.5M | 562.0M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 27.8% | 26.5% | 30.3% | ||
| Avg | 22.0% | 18.0% | 15.3% | ||
| Low | 16.0% | 8.4% | -1.9% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 1.25 | 1.60 | 2.25 | ||
| Avg | 1.18 | 1.53 | 1.86 | ||
| Low | 1.12 | 1.44 | 1.47 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 98.3% | 34.9% | 46.9% | ||
| Avg | 87.8% | 29.3% | 21.6% | ||
| Low | 77.3% | 21.8% | -3.9% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.